All articles by mrinmoyee hazarika
mrinmoyee hazarika
ASLAN doses first subject in alopecia areata therapy trial
The trial will examine the efficacy and safety of farudodstat in patients who have lost at least 50% of their scalp hair.
Antengene gets FDA approval for Phase I trial of cancer drug
ATG-031 is a humanised anti-CD24 monoclonal antibody and is Antengene’s third drug candidate to enter clinical trials in the US.
PepGen obtains Health Canada approval to begin DMD therapy trial
The trial will investigate the safety, tolerability, pharmacokinetics and clinical assessments of PGN-EDO51.
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
The trial will assess the pharmacokinetics, safety, and tolerability of S-892216 in healthy adults.
University of Southampton trial shows spironolactone’s potential for acne
Spironolactone has been used for treating high blood pressure for decades.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
FDA approves Ultragenyx’s Angelman syndrome therapy trial protocol amendment
The amended protocol allows Ultragenyx to match dose ranges in the US with those being used in the cohorts outside of the US.
UK clears OCTP’s Phase I trial application of OCT461201
The trial aims to show the safety, tolerability and pharmacokinetics of OCT461201.
Netramark unveils ChatGPT-based clinical trial de-risking technology
NetraGPT consumes data on specific clinical trial patient subpopulations identified by NetraAI.
Transcenta reports positive data from trial of TST002 for BMD
The Phase I trial evaluated TST002 (Blosozumab) in Chinese postmenopausal women and elder men with reduced bone mineral density.
HiST Pharma receives FDA IND clearance for psoriasis vulgaris drug trial
TC Cream represents the world’s first botanical small-molecule drug for treating psoriasis vulgaris.